Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Bio-Gene Technology Ltd. ( (AU:BGT) ).
Bio-Gene reported its financial and operational progress for the half year to 31 December 2025, highlighting steady advancement of its bio-insecticide portfolio. The company completed its 14th Qcide harvest, advanced biomass pre-treatment and extraction optimisation, and continued investing with partners in refining Flavocide formulations for key applications.
Operationally, Qcide secured listing approval from the U.S. Organic Materials Review Institute as a botanical pesticide under the USDA National Organic Program, while Purdue University researchers presented positive Flavocide efficacy data against tick-borne disease vectors. Bio-Gene also identified additional product applications and faster-path Qcide product opportunities, won A$3 million in U.S. Department of Defense funding for two development programs, undertook strategic partner outreach across Asia, completed an annual strategic review, and strengthened its balance sheet with A$2.46 million raised via a placement and share purchase plan.
The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian biotechnology company developing novel bio-insecticides derived from naturally occurring compounds to tackle insecticide resistance and toxicity. Its lead products, Flavocide and Qcide, target multiple markets including public health, crop protection, grain storage and consumer pest control, aiming to offer effective, nature-based solutions with minimal impact on human health and the environment.
Average Trading Volume: 108,503
Technical Sentiment Signal: Hold
Current Market Cap: A$9.46M
Find detailed analytics on BGT stock on TipRanks’ Stock Analysis page.